person · Reporting owner

Epstein David R

Disclosed activity across 9 companies

Tapewire entity: 1546
SEC CIK: 0001445826

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AgomAb Therapeutics NVAGMB · Entity 5259	Director	October 08, 2026	October 09, 2026
Axcella Health Inc.AXLA · Entity 116059	Director	May 19, 2022	June 03, 2022
Evelo Biosciences, Inc.EVLO · Entity 108468	Director	June 30, 2022	June 30, 2022
INTERNATIONAL FLAVORS & FRAGRANCES INCIFF · Entity 3234	Director	November 02, 2020	November 04, 2020
Opy Acquisition Corp. IOHAA · Entity 133726	Director	October 26, 2021	October 27, 2021
Rubius Therapeutics, Inc.RUBY · Entity 116417	Director	May 12, 2022	May 13, 2022
Senti Biosciences Holdings, Inc.SNTI · Entity 7935	Director	July 13, 2022	July 15, 2022
Tempus AI, Inc.TEM · Entity 1545	Director	September 01, 2026	September 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AgomAb Therapeutics NV

Report date October 08, 2026 · Filed October 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common sharesSEC Table I · non-derivative	Direct	15,000	Reported balance After 2026-10-08 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-10-08 · Purchase · Acquired 5,000 · Balance 15,000 F1: The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

Filing footnotes · ownership attribution and instrument terms

F1: The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

Axcella Health Inc.

Report date May 19, 2022 · Filed June 03, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	209,756	Reported balance After 2022-05-19 transaction · row 1 1 source row Row 1 · 2022-05-19 · Grant · Acquired 47,059 · Balance 209,756 F1: Represents a grant of 47,059 restricted stock units ("RSUs"), each representing a contingent right to receive one share of AXLA common stock. The shares underlying this grant shall vest in twelve equal monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of 47,059 restricted stock units ("RSUs"), each representing a contingent right to receive one share of AXLA common stock. The shares underlying this grant shall vest in twelve equal monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date.

Evelo Biosciences, Inc.

Report date June 30, 2022 · Filed June 30, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	93,932	Ending reported balance After 2022-06-30 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2022-06-30 · Exercise / conversion · Acquired 2,053 · Balance 91,058 F1: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. Row 2 · 2022-06-30 · Exercise / conversion · Acquired 2,874 · Balance 93,932 F1: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2022-06-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-06-30 · Exercise / conversion · Disposed 2,053 · Balance 0 F2: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as chair of the board of directors of the issuer on such vesting dates.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2022-06-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-06-30 · Exercise / conversion · Disposed 2,874 · Balance 0 F3: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as a consultant to the issuer on such vesting dates.

Filing footnotes · ownership attribution and instrument terms

F1: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person.

F2: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as chair of the board of directors of the issuer on such vesting dates.

F3: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as a consultant to the issuer on such vesting dates.

INTERNATIONAL FLAVORS & FRAGRANCES INC

Report date November 02, 2020 · Filed November 04, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Equivalent UnitSEC Table II · derivative / convertible security	Direct	6,397.471	Reported balance After 2020-11-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-11-02 · Grant · Acquired 1,070.715 · Balance 6,397.471 F1: The Stock Equivalent Units ("Units") convert to Common Stock on a one-for-one basis. F2: Units under the Company's deferred compensation plan resulting from deferral of director fees. F3: The Units are payable in Common Stock upon the reporting person ceasing to serve as a member of the Company's Board of Directors. F4: Includes Units acquired during the period upon reinvestment of dividends under the Company's deferred compensation plan during 2020. The transactions were exempt pursuant to Rule 16a-11.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2021-05-06	Direct	1,047	Reported balance Holding disclosure · report date 2020-11-02 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance 1,047 F5: The Restricted Stock Units ("RSUs") convert to Common Stock on a one-for-one basis.

Filing footnotes · ownership attribution and instrument terms

F1: The Stock Equivalent Units ("Units") convert to Common Stock on a one-for-one basis.

F2: Units under the Company's deferred compensation plan resulting from deferral of director fees.

F3: The Units are payable in Common Stock upon the reporting person ceasing to serve as a member of the Company's Board of Directors.

F4: Includes Units acquired during the period upon reinvestment of dividends under the Company's deferred compensation plan during 2020. The transactions were exempt pursuant to Rule 16a-11.

F5: The Restricted Stock Units ("RSUs") convert to Common Stock on a one-for-one basis.

Opy Acquisition Corp. I

Report date October 26, 2021 · Filed October 27, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance Holding disclosure · report date 2021-10-26 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 0

Rubius Therapeutics, Inc.

Report date May 12, 2022 · Filed May 13, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2032-05-11	Direct	499,762	Reported balance After 2022-05-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-05-12 · Grant · Acquired 499,762 · Balance 499,762 F1: This option is fully vested at the time of grant.

Filing footnotes · ownership attribution and instrument terms

F1: This option is fully vested at the time of grant.

Senti Biosciences Holdings, Inc.

Report date July 13, 2022 · Filed July 15, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2032-07-12	Direct	125,000	Reported balance After 2022-07-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-07-13 · Grant · Acquired 125,000 · Balance 125,000 F1: The shares underlying this option vest in 36 substantially equal monthly installments over three years from July 13, 2022, subject to the reporting person's continued service through the applicable vesting date. The vested shares subject to such option shall be exercisable upon the effectiveness of the Issuer's registration statement on Form S-8, registering the shares of the Issuer's 2022 Equity Incentive Plan with the U.S. Securities and Exchange Commission.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest in 36 substantially equal monthly installments over three years from July 13, 2022, subject to the reporting person's continued service through the applicable vesting date. The vested shares subject to such option shall be exercisable upon the effectiveness of the Issuer's registration statement on Form S-8, registering the shares of the Issuer's 2022 Equity Incentive Plan with the U.S. Securities and Exchange Commission.

Tempus AI, Inc.

Report date September 01, 2026 · Filed September 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	30,844	Reported balance After 2026-09-01 transaction · row 1 1 source row Row 1 · 2026-09-01 · Sale · Disposed 250 · Balance 30,844 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 27, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 27, 2024.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Seagen Inc.

Report date December 14, 2023 · Filed December 15, 2023

Section 16 reporting ended · disclosed 2023-12-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-12-14 transaction · row 1 1 source row Row 1 · 2023-12-14 · Disposition to issuer · Disposed 16,407 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $137.96 · Expires 2032-11-09	Direct	Reported balance After 2023-12-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-12-14 · Disposition to issuer · Disposed 2,896 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $137.96 · Expires 2032-11-09	Direct	Reported balance After 2023-12-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-12-14 · Disposition to issuer · Disposed 240,451 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $137.96 · Expires 2032-11-09	Direct	Reported balance After 2023-12-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-12-14 · Disposition to issuer · Disposed 224,000 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-12-14 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-12-14 · Disposition to issuer · Disposed 80,541 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-12-14 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-12-14 · Disposition to issuer · Disposed 39,650 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-12-14 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-12-14 · Disposition to issuer · Disposed 2,644 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-12-14 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-12-14 · Disposition to issuer · Disposed 6,608 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-12-14 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-12-14 · Disposition to issuer · Disposed 3,965 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-12-14 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-12-14 · Disposition to issuer · Disposed 5,286 · Balance 0 F7: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-12-14 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2023-12-14 · Disposition to issuer · Disposed 13,217 · Balance 0 F7: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-12-14 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2023-12-14 · Disposition to issuer · Disposed 7,930 · Balance 0 F7: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").

F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU.

F5: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.

F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance.

F7: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 31, 2022 Filed Jun 1, 2022 16:12 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionCommon Stock	2,052	$0.00	$0.00	Disclosure SEC source: 0001694665-22-000091 · wf-form4_165411435361955.xml · nonDerivative · entry 1 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. F1 · acquired: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. Read SEC document
May 27, 2022 Filed May 31, 2022 16:07 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	PurchaseCommon Stock	17,123	$1.46	$24,999.58	Disclosure SEC source: 0001694665-22-000083 · wf-form4_165402761150511.xml · nonDerivative · entry 1 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,080 Read SEC document
May 19, 2022 Filed Jun 3, 2022 20:30 UTC	Axcella Health Inc. AXLA · Entity 116059	GrantCommon Stock	47,059	$0.00	$0.00	Disclosure SEC source: 0001104659-22-068109 · tm2217610-2_4seq1.xml · nonDerivative · entry 1 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,756 F1 · shares: Represents a grant of 47,059 restricted stock units ("RSUs"), each representing a contingent right to receive one share of AXLA common stock. The shares underlying this grant shall vest in twelve equal monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
May 12, 2022 Filed May 13, 2022 16:20 UTC	Rubius Therapeutics, Inc. RUBY · Entity 116417	GrantStock Option (Right to Buy) · Derivative	499,762	$0.00 Strike: $1.24	$0.00	Disclosure SEC source: 0001179110-22-002998 · edgar.xml · derivative · entry 1 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 499,762 Underlying: Common Stock · 499,762 shares Expires 2032-05-11 F1 · derivative.exercise_date: This option is fully vested at the time of grant. Read SEC document
May 02, 2022 Filed May 2, 2022 16:03 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionRestricted Stock Units · Derivative	2,873	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001694665-22-000073 · wf-form4_165152180271431.xml · derivative · entry 4 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,747 Underlying: Common Stock · 2,873 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as a consultant to the issuer on such vesting dates. F3 · derivative.expiration_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as a consultant to the issuer on such vesting dates. Read SEC document
May 02, 2022 Filed May 2, 2022 16:03 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionRestricted Stock Units · Derivative	2,053	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001694665-22-000073 · wf-form4_165152180271431.xml · derivative · entry 3 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,105 Underlying: Common Stock · 2,053 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as chair of the board of directors of the issuer on such vesting dates. F2 · derivative.expiration_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as chair of the board of directors of the issuer on such vesting dates. Read SEC document
May 02, 2022 Filed May 2, 2022 16:03 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionCommon Stock	2,873	$0.00	$0.00	Disclosure SEC source: 0001694665-22-000073 · wf-form4_165152180271431.xml · nonDerivative · entry 2 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. F1 · acquired: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. Read SEC document
May 02, 2022 Filed May 2, 2022 16:03 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionCommon Stock	2,053	$0.00	$0.00	Disclosure SEC source: 0001694665-22-000073 · wf-form4_165152180271431.xml · nonDerivative · entry 1 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. F1 · acquired: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. Read SEC document
April 21, 2022 Filed Apr 22, 2022 18:07 UTC	Rubius Therapeutics, Inc. RUBY · Entity 116417	PurchaseCommon Stock	30,000	$1.44	$43,329.00	Disclosure SEC source: 0001179110-22-002716 · edgar.xml · nonDerivative · entry 1 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,720,012 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.36 to $1.50, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
March 31, 2022 Filed Apr 1, 2022 16:05 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionRestricted Stock Units · Derivative	2,874	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001694665-22-000049 · wf-form4_164884350436088.xml · derivative · entry 4 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,620 Underlying: Common Stock · 2,874 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as a consultant to the issuer on such vesting dates. F3 · derivative.expiration_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as a consultant to the issuer on such vesting dates. Read SEC document
March 31, 2022 Filed Apr 1, 2022 16:05 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionRestricted Stock Units · Derivative	2,052	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001694665-22-000049 · wf-form4_164884350436088.xml · derivative · entry 3 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,158 Underlying: Common Stock · 2,052 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as chair of the board of directors of the issuer on such vesting dates. F2 · derivative.expiration_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as chair of the board of directors of the issuer on such vesting dates. Read SEC document
March 31, 2022 Filed Apr 1, 2022 16:05 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionCommon Stock	2,874	$0.00	$0.00	Disclosure SEC source: 0001694665-22-000049 · wf-form4_164884350436088.xml · nonDerivative · entry 2 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. F1 · acquired: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. Read SEC document
March 31, 2022 Filed Apr 1, 2022 16:05 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionCommon Stock	2,052	$0.00	$0.00	Disclosure SEC source: 0001694665-22-000049 · wf-form4_164884350436088.xml · nonDerivative · entry 1 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. F1 · acquired: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. Read SEC document
March 18, 2022 Filed Mar 21, 2022 20:30 UTC	Axcella Health Inc. AXLA · Entity 116059	Exercise / conversionRestricted Stock Units · Derivative	1,535	$0.00	$0.00	Disclosure SEC source: 0001104659-22-036134 · tm229468-6_4seq1.xml · derivative · entry 3 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,535 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AXLA common stock. F3 · derivative.exercise_date: The RSUs are fully vested as of the date hereof. F3 · derivative.expiration_date: The RSUs are fully vested as of the date hereof. Read SEC document
March 18, 2022 Filed Mar 21, 2022 20:30 UTC	Axcella Health Inc. AXLA · Entity 116059	Exercise / conversionCommon Stock	1,535	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-22-036134 · tm229468-6_4seq1.xml · nonDerivative · entry 1 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AXLA common stock. Read SEC document
March 17, 2022 Filed Mar 21, 2022 20:30 UTC	Axcella Health Inc. AXLA · Entity 116059	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $2.51	$0.00	Disclosure SEC source: 0001104659-22-036134 · tm229468-6_4seq1.xml · derivative · entry 2 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-03-16 F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) May 19, 2023 and (ii) the date of the 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service at such time. Read SEC document
March 16, 2022 Filed Mar 18, 2022 12:30 UTC	Axcella Health Inc. AXLA · Entity 116059	PurchaseCommon Stock	26,178	$1.91	$49,999.98	Disclosure SEC source: 0001104659-22-035343 · tm229468-2_4seq1.xml · nonDerivative · entry 1 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,162 F1 · shares: Represents the common stock of Axcella Health Inc. acquired by the reporting person in a registered direct offering on March 16, 2022, at a price of $1.91 per share. Read SEC document
February 28, 2022 Filed Mar 1, 2022 16:07 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionRestricted Stock Units · Derivative	2,873	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001694665-22-000038 · wf-form4_164616882870990.xml · derivative · entry 4 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,494 Underlying: Common Stock · 2,873 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as a consultant to the issuer on such vesting dates. F3 · derivative.expiration_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as a consultant to the issuer on such vesting dates. Read SEC document
February 28, 2022 Filed Mar 1, 2022 16:07 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionRestricted Stock Units · Derivative	2,053	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001694665-22-000038 · wf-form4_164616882870990.xml · derivative · entry 3 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,210 Underlying: Common Stock · 2,053 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as chair of the board of directors of the issuer on such vesting dates. F2 · derivative.expiration_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as chair of the board of directors of the issuer on such vesting dates. Read SEC document
February 28, 2022 Filed Mar 1, 2022 16:07 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionCommon Stock	2,873	$0.00	$0.00	Disclosure SEC source: 0001694665-22-000038 · wf-form4_164616882870990.xml · nonDerivative · entry 2 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. F1 · acquired: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. Read SEC document
February 28, 2022 Filed Mar 1, 2022 16:07 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionCommon Stock	2,053	$0.00	$0.00	Disclosure SEC source: 0001694665-22-000038 · wf-form4_164616882870990.xml · nonDerivative · entry 1 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. F1 · acquired: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. Read SEC document
February 18, 2022 Filed Feb 23, 2022 21:19 UTC	Axcella Health Inc. AXLA · Entity 116059	Exercise / conversionRestricted Stock Units · Derivative	1,534	$0.00	$0.00	Disclosure SEC source: 0001104659-22-026106 · tm227475-1_4seq1.xml · derivative · entry 2 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,535 Underlying: Common Stock · 1,534 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AXLA common stock. F2 · derivative.exercise_date: The RSUs shall vest in 12 equal monthly installments, with the first installment vested on April 18, 2021. F2 · derivative.expiration_date: The RSUs shall vest in 12 equal monthly installments, with the first installment vested on April 18, 2021. Read SEC document
February 18, 2022 Filed Feb 23, 2022 21:19 UTC	Axcella Health Inc. AXLA · Entity 116059	Exercise / conversionCommon Stock	1,534	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-22-026106 · tm227475-1_4seq1.xml · nonDerivative · entry 1 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AXLA common stock. Read SEC document
January 31, 2022 Filed Jan 31, 2022 17:06 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionRestricted Stock Units · Derivative	2,873	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001694665-22-000027 · wf-form4_164366678792571.xml · derivative · entry 4 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,367 Underlying: Common Stock · 2,873 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as a consultant to the issuer on such vesting dates. F3 · derivative.expiration_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as a consultant to the issuer on such vesting dates. Read SEC document
January 31, 2022 Filed Jan 31, 2022 17:06 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionRestricted Stock Units · Derivative	2,052	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001694665-22-000027 · wf-form4_164366678792571.xml · derivative · entry 3 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,263 Underlying: Common Stock · 2,052 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as chair of the board of directors of the issuer on such vesting dates. F2 · derivative.expiration_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as chair of the board of directors of the issuer on such vesting dates. Read SEC document
January 31, 2022 Filed Jan 31, 2022 17:06 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionCommon Stock	2,873	$0.00	$0.00	Disclosure SEC source: 0001694665-22-000027 · wf-form4_164366678792571.xml · nonDerivative · entry 2 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. F1 · acquired: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. Read SEC document
January 31, 2022 Filed Jan 31, 2022 17:06 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionCommon Stock	2,052	$0.00	$0.00	Disclosure SEC source: 0001694665-22-000027 · wf-form4_164366678792571.xml · nonDerivative · entry 1 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. F1 · acquired: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. Read SEC document
January 18, 2022 Filed Jan 20, 2022 21:30 UTC	Axcella Health Inc. AXLA · Entity 116059	Exercise / conversionRestricted Stock Units · Derivative	1,535	$0.00	$0.00	Disclosure SEC source: 0001104659-22-005947 · tm223928-1_4seq1.xml · derivative · entry 2 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,069 Underlying: Common Stock · 1,535 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AXLA common stock. F2 · derivative.exercise_date: The RSUs shall vest in 12 equal monthly installments, with the first installment vested on April 18, 2021. F2 · derivative.expiration_date: The RSUs shall vest in 12 equal monthly installments, with the first installment vested on April 18, 2021. Read SEC document
January 18, 2022 Filed Jan 20, 2022 21:30 UTC	Axcella Health Inc. AXLA · Entity 116059	Exercise / conversionCommon Stock	1,535	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-22-005947 · tm223928-1_4seq1.xml · nonDerivative · entry 1 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AXLA common stock. Read SEC document
December 31, 2021 Filed Jan 3, 2022 16:23 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionRestricted Stock Units · Derivative	2,874	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001694665-22-000002 · wf-form4_164124499187524.xml · derivative · entry 4 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,240 Underlying: Common Stock · 2,874 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as a consultant to the issuer on such vesting dates. F3 · derivative.expiration_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as a consultant to the issuer on such vesting dates. Read SEC document
December 31, 2021 Filed Jan 3, 2022 16:23 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionRestricted Stock Units · Derivative	2,052	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001694665-22-000002 · wf-form4_164124499187524.xml · derivative · entry 3 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,315 Underlying: Common Stock · 2,052 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as chair of the board of directors of the issuer on such vesting dates. F2 · derivative.expiration_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as chair of the board of directors of the issuer on such vesting dates. Read SEC document
December 31, 2021 Filed Jan 3, 2022 16:23 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionCommon Stock	2,874	$0.00	$0.00	Disclosure SEC source: 0001694665-22-000002 · wf-form4_164124499187524.xml · nonDerivative · entry 2 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. F1 · acquired: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. Read SEC document
December 31, 2021 Filed Jan 3, 2022 16:23 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionCommon Stock	2,052	$0.00	$0.00	Disclosure SEC source: 0001694665-22-000002 · wf-form4_164124499187524.xml · nonDerivative · entry 1 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. F1 · acquired: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. Read SEC document
December 17, 2021 Filed Dec 20, 2021 21:15 UTC	Axcella Health Inc. AXLA · Entity 116059	Exercise / conversionRestricted Stock Units · Derivative	1,535	$0.00	$0.00	Disclosure SEC source: 0001104659-21-151698 · tm2135916-1_4seq1.xml · derivative · entry 2 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,604 Underlying: Common Stock · 1,535 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AXLA common stock. F2 · derivative.exercise_date: The RSUs shall vest in 12 equal monthly installments, with the first installment vested on April 18, 2021. F2 · derivative.expiration_date: The RSUs shall vest in 12 equal monthly installments, with the first installment vested on April 18, 2021. Read SEC document
December 17, 2021 Filed Dec 20, 2021 21:15 UTC	Axcella Health Inc. AXLA · Entity 116059	Exercise / conversionCommon Stock	1,535	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-21-151698 · tm2135916-1_4seq1.xml · nonDerivative · entry 1 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AXLA common stock. Read SEC document
November 30, 2021 Filed Dec 1, 2021 16:39 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionRestricted Stock Units · Derivative	2,873	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001694665-21-000152 · wf-form4_163839473705119.xml · derivative · entry 4 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,114 Underlying: Common Stock · 2,873 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as a consultant to the issuer on such vesting dates. F3 · derivative.expiration_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as a consultant to the issuer on such vesting dates. Read SEC document
November 30, 2021 Filed Dec 1, 2021 16:39 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionRestricted Stock Units · Derivative	2,053	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001694665-21-000152 · wf-form4_163839473705119.xml · derivative · entry 3 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,367 Underlying: Common Stock · 2,053 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as chair of the board of directors of the issuer on such vesting dates. F2 · derivative.expiration_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as chair of the board of directors of the issuer on such vesting dates. Read SEC document
November 30, 2021 Filed Dec 1, 2021 16:39 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionCommon Stock	2,873	$0.00	$0.00	Disclosure SEC source: 0001694665-21-000152 · wf-form4_163839473705119.xml · nonDerivative · entry 2 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. F1 · acquired: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. Read SEC document
November 30, 2021 Filed Dec 1, 2021 16:39 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionCommon Stock	2,053	$0.00	$0.00	Disclosure SEC source: 0001694665-21-000152 · wf-form4_163839473705119.xml · nonDerivative · entry 1 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. F1 · acquired: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. Read SEC document
November 18, 2021 Filed Nov 22, 2021 23:04 UTC	Axcella Health Inc. AXLA · Entity 116059	Exercise / conversionRestricted Stock Units · Derivative	1,534	$0.00	$0.00	Disclosure SEC source: 0001104659-21-142660 · tm2133722d1_4seq1.xml · derivative · entry 2 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,139 Underlying: Common Stock · 1,534 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AXLA common stock. F2 · derivative.exercise_date: The RSUs shall vest in 12 equal monthly installments, with the first installment vested on April 18, 2021. F2 · derivative.expiration_date: The RSUs shall vest in 12 equal monthly installments, with the first installment vested on April 18, 2021. Read SEC document
November 18, 2021 Filed Nov 22, 2021 23:04 UTC	Axcella Health Inc. AXLA · Entity 116059	Exercise / conversionCommon Stock	1,534	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-21-142660 · tm2133722d1_4seq1.xml · nonDerivative · entry 1 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AXLA common stock. Read SEC document
November 01, 2021 Filed Nov 1, 2021 17:22 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionRestricted Stock Units · Derivative	2,873	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001694665-21-000150 · wf-form4_163580175124646.xml · derivative · entry 4 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,987 Underlying: Common Stock · 2,873 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as a consultant to the issuer on such vesting dates. F3 · derivative.expiration_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as a consultant to the issuer on such vesting dates. Read SEC document
November 01, 2021 Filed Nov 1, 2021 17:22 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionRestricted Stock Units · Derivative	2,052	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001694665-21-000150 · wf-form4_163580175124646.xml · derivative · entry 3 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,420 Underlying: Common Stock · 2,052 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as chair of the board of directors of the issuer on such vesting dates. F2 · derivative.expiration_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as chair of the board of directors of the issuer on such vesting dates. Read SEC document
November 01, 2021 Filed Nov 1, 2021 17:22 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionCommon Stock	2,873	$0.00	$0.00	Disclosure SEC source: 0001694665-21-000150 · wf-form4_163580175124646.xml · nonDerivative · entry 2 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. F1 · acquired: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. Read SEC document
November 01, 2021 Filed Nov 1, 2021 17:22 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionCommon Stock	2,052	$0.00	$0.00	Disclosure SEC source: 0001694665-21-000150 · wf-form4_163580175124646.xml · nonDerivative · entry 1 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. F1 · acquired: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. Read SEC document
October 18, 2021 Filed Oct 19, 2021 20:31 UTC	Axcella Health Inc. AXLA · Entity 116059	Exercise / conversionRestricted Stock Units · Derivative	1,535	$0.00	$0.00	Disclosure SEC source: 0001104659-21-127599 · tm2130408-1_4seq1.xml · derivative · entry 2 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,673 Underlying: Common Stock · 1,535 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AXLA common stock. F2 · derivative.exercise_date: The RSUs shall vest in 12 equal monthly installments, with the first installment vested on April 18, 2021. F2 · derivative.expiration_date: The RSUs shall vest in 12 equal monthly installments, with the first installment vested on April 18, 2021. Read SEC document
October 18, 2021 Filed Oct 19, 2021 20:31 UTC	Axcella Health Inc. AXLA · Entity 116059	Exercise / conversionCommon Stock	1,535	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-21-127599 · tm2130408-1_4seq1.xml · nonDerivative · entry 1 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AXLA common stock. Read SEC document
October 01, 2021 Filed Oct 1, 2021 16:42 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionRestricted Stock Units · Derivative	2,874	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001694665-21-000134 · wf-form4_163312090860233.xml · derivative · entry 4 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,860 Underlying: Common Stock · 2,874 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as a consultant to the issuer on such vesting dates. F3 · derivative.expiration_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as a consultant to the issuer on such vesting dates. Read SEC document
October 01, 2021 Filed Oct 1, 2021 16:42 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionRestricted Stock Units · Derivative	2,053	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001694665-21-000134 · wf-form4_163312090860233.xml · derivative · entry 3 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,472 Underlying: Common Stock · 2,053 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as chair of the board of directors of the issuer on such vesting dates. F2 · derivative.expiration_date: The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as chair of the board of directors of the issuer on such vesting dates. Read SEC document
October 01, 2021 Filed Oct 1, 2021 16:42 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	Exercise / conversionCommon Stock	2,874	$0.00	$0.00	Disclosure SEC source: 0001694665-21-000134 · wf-form4_163312090860233.xml · nonDerivative · entry 2 Epstein David R · CIK 0001445826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. F1 · acquired: Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.